LixiLan-O Study
Download this clinical summary to read about the benefits of Suliqua in the phase III LixiLan-O study. The study is demonstrating the benefits of Suliqua, a titratable fixed-ratio combination of insulin glargine + lixisenatide vs insulin glargine + lixisenatide monocomponents. This was done in type 2 diabetes patients, inadequately controlled on oral agents.
Rosenstock J, et al. Diabetes Care. 2016; 39: 2026–35.
Always up to date?
Webinars, evidence, expert videos, peer-to-peer events… Do you want to be the first to know when new, relevant information is available? Let us know and we’ll send you a message.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to the Sanofi drug safety department on 0800 0902 314. Alternatively, send via email to UK-drugsafety@sanofi.com. Prescribing information will be available at the meeting.